Prognostic Impact of Copeptin and Mid-Regional
Pro-Adrenomedullin in Chronic Heart Failure with Regard to
Comorbidities

J 2018

Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities

ŠPINAROVÁ, Lenka, Monika ŠPINAROVÁ, Monika PÁVKOVÁ GOLDBERGOVÁ, Jindřich ŠPINAR, Jiří PAŘENICA et. al.

Basic information

Original name

Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities

Authors

ŠPINAROVÁ, Lenka (203 Czech Republic, guarantor, belonging to the institution), Monika ŠPINAROVÁ (203 Czech Republic, belonging to the institution), Monika PÁVKOVÁ GOLDBERGOVÁ (203 Czech Republic, belonging to the institution), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), Ondřej LUDKA (203 Czech Republic, belonging to the institution), Karel LÁBR (203 Czech Republic), F. MALEK (203 Czech Republic), P. OSTADAL (203 Czech Republic), D. VONDRAKOVA (203 Czech Republic), Josef TOMANDL (203 Czech Republic, belonging to the institution), Jana VEVERKOVÁ (203 Czech Republic, belonging to the institution), Jolana LIPKOVÁ (203 Czech Republic, belonging to the institution), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution) and Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution)

Edition

Journal of Cardiovascular & Diseases Diagnosis, (Romania), OMICS International, 2018, 2329-9517

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Romania

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/18:00103531

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.4172/2329-9517.1000326

Keywords in English

Chronic heart failure; AHEAD score; Copeptin; Midregional pro-adrenomedullin; Prognosis

Abstract

V originále

The aim of the study is to evaluate the impact of new humoral substances: copeptin and mid- regional proadrenomedullin (MR-proADM) on one-year survival of patients with stable systolic chronic heart failure (CHF) and to compare them with AHEAD score assessing the comorbidities. The FAR NHL (FARmacology and NeuroHumoraL activation) registry is a database of patients with stable CHF (ejection fraction (EF) <50%) treated in specialized HF departments. AHEAD score is a simple bed-side mortality predictive model based on age and comorbidities. Primary endpoint after 1-year follow-up was: death or hospitalization for decompensation of HF or heart transplantation or LVAD implantation. To whole FAR NHL registry, a total amount of 1088 patients were included, in 552 of them the levels of copeptin and MR-proADM were available. Mean age was 65+12 years, mean EF was 31+9%. Patients without primary endpoint were assigned as group A (469 pts), those with the primary endpoint group B (83 pts). There were statistically significant differences between the groups in the levels of copeptin: group A median 15.9 pmol/l (3.4-50.9) vs group B 23.7 pmol/l(5.0-89.44) (p<0.001), MR-proADM: group A median 0.63 nmol/l(0.32-1.34) vs group B 0.74 nmol/l (0.4-1.94) (p<0.001). Relationship of AHEAD score to primary endpoint in the first year of follow-up was not significant, but within 24th month it reached statistical significance: p= 0.017. Patients with higher AHEAD score (more comorbidities) reached more often the primary end-point.

Citovat

ŠPINAROVÁ, Lenka, Monika ŠPINAROVÁ, Monika PÁVKOVÁ GOLDBERGOVÁ, Jindřich ŠPINAR, Jiří PAŘENICA, Ondřej LUDKA, Karel LÁBR, F. MALEK, P. OSTADAL, D. VONDRAKOVA, Josef TOMANDL, Jana VEVERKOVÁ, Jolana LIPKOVÁ, Klára BENEŠOVÁ and Jiří JARKOVSKÝ. Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities. Journal of Cardiovascular & Diseases Diagnosis. (Romania): OMICS International, 2018, vol. 6, No 4, p. 1-5. ISSN 2329-9517. Available from: https://dx.doi.org/10.4172/2329-9517.1000326.

@article{1430497,
   author = {Špinarová, Lenka and Špinarová, Monika and Pávková Goldbergová, Monika and Špinar, Jindřich and Pařenica, Jiří and Ludka, Ondřej and Lábr, Karel and Malek, F. and Ostadal, P. and Vondrakova, D. and Tomandl, Josef and Veverková, Jana and Lipková, Jolana and Benešová, Klára and Jarkovský, Jiří},
   article_location = {(Romania)},
   article_number = {4},
   doi = {http://dx.doi.org/10.4172/2329-9517.1000326},
   keywords = {Chronic heart failure; AHEAD score; Copeptin; Midregional pro-adrenomedullin; Prognosis},
   language = {eng},
   issn = {2329-9517},
   journal = {Journal of Cardiovascular & Diseases Diagnosis},
   title = {Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities},
   volume = {6},
   year = {2018}
}

TY  - JOUR
ID  - 1430497
AU  - Špinarová, Lenka - Špinarová, Monika - Pávková Goldbergová, Monika - Špinar, Jindřich - Pařenica, Jiří - Ludka, Ondřej - Lábr, Karel - Malek, F. - Ostadal, P. - Vondrakova, D. - Tomandl, Josef - Veverková, Jana - Lipková, Jolana - Benešová, Klára - Jarkovský, Jiří
PY  - 2018
TI  - Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities
JF  - Journal of Cardiovascular & Diseases Diagnosis
VL  - 6
IS  - 4
SP  - 1-5
EP  - 1-5
PB  - OMICS International
SN  - 23299517
KW  - Chronic heart failure
KW  - AHEAD score
KW  - Copeptin
KW  - Midregional pro-adrenomedullin
KW  - Prognosis
N2  - The aim of the study is to evaluate the impact of new humoral substances: copeptin and mid- regional proadrenomedullin (MR-proADM) on one-year survival of patients with stable systolic chronic heart failure (CHF) and to compare them with AHEAD score assessing the comorbidities. The FAR NHL (FARmacology and NeuroHumoraL activation) registry is a database of patients with stable CHF (ejection fraction (EF) <50%) treated in specialized HF departments. AHEAD score is a simple bed-side mortality predictive model based on age and comorbidities. Primary endpoint after 1-year follow-up was: death or hospitalization for decompensation of HF or heart transplantation or LVAD implantation. To whole FAR NHL registry, a total amount of 1088 patients were included, in 552 of them the levels of copeptin and MR-proADM were available. Mean age was 65+12 years, mean EF was 31+9%. Patients without primary endpoint were assigned as group A (469 pts), those with the primary endpoint group B (83 pts). There were statistically significant differences between the groups in the levels of copeptin: group A median 15.9 pmol/l (3.4-50.9) vs group B 23.7 pmol/l(5.0-89.44) (p<0.001), MR-proADM: group A median 0.63 nmol/l(0.32-1.34) vs group B 0.74 nmol/l (0.4-1.94) (p<0.001). Relationship of AHEAD score to primary endpoint in the first year of follow-up was not significant, but within 24th month it reached statistical significance: p= 0.017. Patients with higher AHEAD score (more comorbidities) reached more often the primary end-point.
ER  -

ŠPINAROVÁ, Lenka, Monika ŠPINAROVÁ, Monika PÁVKOVÁ GOLDBERGOVÁ, Jindřich ŠPINAR, Jiří PAŘENICA, Ondřej LUDKA, Karel LÁBR, F. MALEK, P. OSTADAL, D. VONDRAKOVA, Josef TOMANDL, Jana VEVERKOVÁ, Jolana LIPKOVÁ, Klára BENEŠOVÁ and Jiří JARKOVSKÝ. Prognostic Impact of Copeptin and Mid-Regional Pro-Adrenomedullin in Chronic Heart Failure with Regard to Comorbidities. \textit{Journal of Cardiovascular \&{} Diseases Diagnosis}. (Romania): OMICS International, 2018, vol.~6, No~4, p.~1-5. ISSN~2329-9517. Available from: https://dx.doi.org/10.4172/2329-9517.1000326.

Detailed Information on Publication Record